Prasugrel

Summary

Prasugrel (CHEMBL1201772) is an approved small molecule (ATC B01AC22); indicated across 15 conditions including thrombotic disease and myocardial infarction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B01AC22
• Indications: 15 conditions
• Clinical trials: 135
• Chemistry: 373.4 Da · C20H20FNO3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201772
Name	Prasugrel
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6918456
ChEBI	CHEBI:87723
ATC	B01AC22
Molecular formula	C20H20FNO3S
Molecular weight	373.4
InChIKey	DTGLZDAWLRGWQN-UHFFFAOYSA-N

SMILES: CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4

IUPAC name: [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate

ChEBI definition: A member of the class of thienopyridines that is 2-acetoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the amino hydrogen is replaced by a 2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl group.

Also known as: Efient, LY-640315, NSC-759625, Prasugrel, SID124899264, SID174006898, prasugrel, PRASUGREL

Parent form; salt/anhydrous children: CHEMBL1201773, CHEMBL6068340

Patent coverage: 314 distinct patent families (844 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 654 (77%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Androgen receptor, P2Y purinoceptor 12, Muscarinic acetylcholine receptor M2, Mu-type opioid receptor, Adenosine receptor A3, Bile salt export pump.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P2RY12	5.75	IC50	1800	nM	CHEMBL_ACT_24689695
ABCB11	5.46	AC50	3500	nM	CHEMBL_ACT_25127020
AR	5.18	AC50	6566	nM	CHEMBL_ACT_25203487

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	3	MONDO:0000831	HP:0004419
myocardial infarction	3	MONDO:0005068	EFO:0000612
acute coronary syndrome	3	MONDO:0005542	EFO:0005672
atrial fibrillation	3	MONDO:0004981	EFO:0000275
ST-elevation myocardial infarction	3	MONDO:0041656	EFO:0008585
coronary artery disorder	3	MONDO:0005010	EFO:0001645
pneumonia	3	MONDO:0005249	EFO:0003106
influenza	3	MONDO:0005812	EFO:0007328
sickle cell disease	3	MONDO:0011382	MONDO:0011382
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
chronic kidney disease	3	MONDO:0005300	MONDO:0024327
heart disorder	2	MONDO:0005267	EFO:0003777
asthma	2	MONDO:0004979	MONDO:0004979
cardiovascular disorder	2	MONDO:0004995	EFO:0000319
HIV infectious disease	1	MONDO:0005109	EFO:0000764

Clinical trials

Total trials: 135.

Phase distribution

Phase	Trials
PHASE4	66
PHASE3	28
PHASE2	15
PHASE1	12
Not specified	12
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05767723	PHASE4	ACTIVE_NOT_RECRUITING	Platelet Sub-study of the Neomindset Trial
NCT06588595	PHASE4	RECRUITING	The Switching Antiplatelet-9 (SWAP-9) Study
NCT06691191	PHASE4	RECRUITING	Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
NCT06718179	PHASE4	RECRUITING	Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents
NCT06821191	PHASE4	RECRUITING	Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
NCT06916520	PHASE4	RECRUITING	Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)
NCT07025148	PHASE4	RECRUITING	Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
NCT07507500	PHASE4	NOT_YET_RECRUITING	Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
NCT00827411	PHASE4	COMPLETED	Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy
NCT00976092	PHASE4	UNKNOWN	Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
NCT01014624	PHASE4	COMPLETED	Prasugrel/Clopidogrel Maintenance Dose Washout Study
NCT01099566	PHASE4	COMPLETED	The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation
NCT01135667	PHASE4	COMPLETED	Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
NCT01158846	PHASE4	UNKNOWN	Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
NCT01201772	PHASE4	COMPLETED	Prasugrel Re-load Strategies
NCT01260584	PHASE4	COMPLETED	The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
NCT01305369	PHASE4	COMPLETED	The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma
NCT01339026	PHASE4	TERMINATED	Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01365221	PHASE4	COMPLETED	The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
NCT01452152	PHASE4	TERMINATED	Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
NCT01456364	PHASE4	UNKNOWN	Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
NCT01463150	PHASE4	COMPLETED	Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
NCT01463163	PHASE4	COMPLETED	Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
NCT01493999	PHASE4	COMPLETED	Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
NCT01510171	PHASE4	COMPLETED	Rapid Activity of Platelet Inhibitor Drugs Study
NCT01538446	PHASE4	COMPLETED	Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
NCT01612884	PHASE4	TERMINATED	Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
NCT01642940	PHASE4	COMPLETED	Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study
NCT01642966	PHASE4	COMPLETED	Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
NCT01700322	PHASE4	COMPLETED	Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study
NCT01777503	PHASE4	COMPLETED	The Elderly ACS II Trial
NCT01789814	PHASE4	COMPLETED	Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
NCT01805570	PHASE4	COMPLETED	Rapid Activity of Platelet Inhibitor Drugs Study 2
NCT01869309	PHASE4	UNKNOWN	Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
NCT01944800	PHASE4	COMPLETED	Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
NCT01951001	PHASE4	COMPLETED	Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome
NCT01957540	PHASE4	COMPLETED	Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease
NCT01959451	PHASE4	COMPLETED	Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial
NCT02032303	PHASE4	UNKNOWN	Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .
NCT02065479	PHASE4	COMPLETED	A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for prasugrel and CYP2C19	DPWG	CYP2C19

PharmGKB also curates 10 clinical and 49 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).